Tiêu đề Vildagluse Binder 2023.pdf ✅

For Healthcare Professionals only 1 HF0089A4592/122022 11/12/2023

Decision cycle for patient-centered glycemic management in type 2 diabetes. (1) ASCVD = Atherosclerotic Cardiovascular Disease CKD = Chronic Kidney Disease HF = Heart Failure DSMES = Diabetes Self-Management Education and Support BGM = Blood Glucose Monitoring REVIEW AND AGREE ON MANAGEMENT PLAN ONGOING MONITORING AND SUPPORT INCLUDING IMPLEMENT MANAGEMENT PLAN ASSESS KEY PATIENT CHARACTERISTICS CONSIDER SPECIFIC FACTORS THAT IMPACT CHOICE OF TREATMENT SHARED DECISION-MAKING TO CREATE A MANAGEMENT PLAN AGREE ON MANAGEMENT PLAN Review management plan Mutual agreement on changes Ensure agreed modification of therapy is implemented in a timely fashion to avoid clinical inertia Decision cycle undertaken regularly (at least once/twice a year) Emotional well-being Check tolerability of medication Monitor glycemic status Biofeedback including BGM, weight, step count, HbA1c, blood pressure, lipids Patients not meeting goals generally should be seen at least every 3 months as long as progress is being made, more frequent contact initially is often desirable for DSMES Current lifestyle Comorbidities, i.e., ASCVD, CKD, HF Clinical characteristics, i.e., age, HbA1c, weight Issues such as motivation and depression Cultural and socioeconomic context Individualized HbA1c target Impact on weight and hypoglycemia Side effect profile of medication Complexity of regimen, i.e., frequency, mode of administration Choose regimen to optimize adherence and persistence Access, cost, and availability of medication Involves an educated and informed patient (and their family/caregiver) Seeks patient preferences Effective consultation includes motivational interviewing, goal setting, and shared decision-making Empowers the patient Ensures access to DSMES Specify SMART goals: - Specific - Measurable - Achievable - Realistic - Time limited 3 HF0089A4592/122022 11/12/2023